What does toujeo bind to albumin?

See the DrugPatentWatch profile for toujeo

What does Toujeo bind to in the body?

Toujeo (insulin glargine U-300) binds primarily to albumin in the bloodstream and in the interstitial fluid. This albumin binding helps keep the insulin in a reservoir-like state, which supports a slower, more sustained release after injection. As the insulin gradually dissociates from albumin, it becomes available to exert its glucose-lowering effect over time.

Why does albumin binding matter for Toujeo’s duration?

Because insulin glargine U-300 associates with albumin and then dissociates slowly, its pharmacokinetic profile is more prolonged than insulin products that do not rely as much on albumin association. That slow dissociation is one reason Toujeo is designed for long-acting, once-daily dosing.

Is this albumin binding the same as for other insulin products?

Toujeo’s specific formulation is insulin glargine U-300, and insulin glargine’s extended action depends in part on how it associates with albumin compared with other insulin types. The exact extent and clinical impact can differ across insulin analogs, but the albumin association is a key mechanism linked to Toujeo’s longer effect.